💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tinzaparin Sodium

CHEMBL1201414 Phase 4 ได้รับการอนุมัติ Oligosaccharide
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Tinzaparin sodium is a low molecular weight heparin (LMWH) derived by enzymatic depolymerization of unfractionated heparin that primarily inhibits factor Xa through antithrombin III, with lesser anti-IIa (thrombin) activity, providing predictable anticoagulation with subcutaneous administration. It is used for the prevention and treatment of deep vein thrombosis, pulmonary embolism, and anticoagulation in certain cancer patients with venous thromboembolism. Its predictable pharmacokinetics allow once-daily dosing without routine monitoring in most patients.

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Hypertension Breast Cancer Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Tinzaparin sodium is a low molecular weight heparin (LMWH) derived by enzymatic depolymerization of unfractionated heparin that primarily inhibits factor Xa through antithrombin III, with lesser anti-IIa (thrombin) activity, providing predictable anticoagulation with subcutaneous administration. It is used for the prevention and treatment of deep vein thrombosis, pulmonary embolism, and anticoagulation in certain cancer patients with venous thromboembolism. Its predictable pharmacokinetics allow once-daily dosing without routine monitoring in most patients.

Yes, Tinzaparin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201414. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.